Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib (SHR0302) in Severe Alopecia Areata
NCT05470413Phase 3Active, not recruiting
- Sponsor
- Reistone Biopharma
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in alopecia areata, sponsored by Reistone Biopharma. Started Apr 2022; status: active, not recruiting.
02
Drugs
ivarmacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05470413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470413.